Composition for inhibiting activity

A carbazochrome-based composition inhibits oral tissue collagen-degrading proteases to prevent gingivitis and periodontitis, offering effective inflammation suppression and improved application flexibility.

JP2024159646APending Publication Date: 2024-11-08DAIICHI SANKYO HEALTHCARE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024071217
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-26
Filing Date
2024-04-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for gingivitis and periodontitis do not effectively suppress the progression of these conditions, and strong-smelling substances like hinokitiol limit application flexibility.

Method used

A composition containing carbazochrome as an active ingredient is developed to inhibit the activity of oral tissue collagen-degrading proteases, including cysteine proteases and matrix metalloproteinases, which are involved in the degradation of oral tissue collagen, thereby suppressing the progression of gingivitis and periodontitis.

Benefits of technology

The composition effectively suppresses the activity of oral tissue collagen-degrading proteases, reducing inflammation and improving application flexibility by minimizing odor, thus effectively preventing gingivitis and periodontitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159646000001
    Figure 2024159646000001
  • Figure 2024159646000002
    Figure 2024159646000002
  • Figure 2024159646000003
    Figure 2024159646000003
Patent Text Reader

Abstract

To provide a novel technique for inhibiting the activity of collagen-degrading proteases in oral tissues.SOLUTION: Provided is a composition for inhibiting the activity of collagen-degrading proteases in oral tissues, comprising carbazochrome as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for inhibiting activity, and more specifically, to a composition for inhibiting the activity of collagen-degrading proteases in oral tissues. [Background technology]

[0002] Techniques relating to the treatment of periodontal disease are described in Patent Document 1 and Non-Patent Document 1. Patent Document 1 describes (paragraph 0005) a technology aimed at providing a periodontal tissue regenerating agent that promotes the regeneration of periodontal tissue more effectively and safely without the need for surgery, a periodontal tissue regenerating method using the periodontal tissue regenerating agent, a periodontal tissue proliferation / activation agent, and a periodontal tissue anti-aging agent. The technology describes a periodontal tissue regenerating agent containing at least one selected from the group consisting of peppermint oil, lily extract, pearl protein extract, aloe extract, dipotassium glycyrrhizinate, licorice extract, isoamyl isovalerate, fennel oil, sodium citrate, L-glutamic acid hydrochloride, diethyl sebacate, thymol, concentrated glycerin, honey, hesperidin, peppermint essence, benzyl alcohol, D-mannitol, methylcellulose, and carbazochrome (claim 1), and states that such an agent can be used for the treatment of periodontal disease and the treatment of periodontal ligament destroyed by periodontal disease (claims 5 and 6). Furthermore, it is stated that, among the above active ingredients, carbazochrome is a hemostatic agent (paragraph 0044).

[0003] Non-Patent Document 1 describes an example in which carbazochrome is used as an anti-inflammatory agent in a gingival massage drug for treating marginal periodontitis and gingivitis.

[0004] On the other hand, Patent Document 2 describes a composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, which contains at least one active ingredient selected from the group consisting of hinokitiol and peony processed products (Claim 1). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2016-153396 A [Patent Document 2] JP 2020-109071 A [Non-patent literature]

[0006] [Non-Patent Document 1] Satoshi Yamashita et al., "Blind Clinical Evaluation of the Gingival Massage Drug "LPD" for Marginal Periodontitis and Gingivitis," Journal of the Japanese Academy of Periodontology, Vol. 26, No. 2, 1984, p. 397-420 Summary of the Invention [Problem to be solved by the invention]

[0007] The techniques described in Patent Document 1 and Non-Patent Document 1 are techniques for treating gingivitis or periodontitis accompanying its progression, but are not intended to inhibit the occurrence of these diseases themselves. Furthermore, in the technology described in Patent Document 2, the active ingredient, hinokitiol, is a substance with a strong odor and a characteristic fragrance, so there was room for improvement in terms of the flexibility of the range of application.

[0008] Therefore, the present invention provides a new technique for inhibiting the activity of collagen-degrading proteases in oral tissues. [Means for solving the problem]

[0009] According to the present invention, there are provided the following activity suppressing composition and method for producing the same. [1] A composition for inhibiting the activity of collagen-degrading proteases in oral tissues, comprising carbazochrome as an active ingredient. [2] The activity-inhibiting composition described in [1], wherein the oral tissue collagen-degrading protease is at least one selected from the group consisting of cysteine ​​proteases produced by periodontal disease-causing bacteria and matrix metalloproteinase (MMP)-1, MMP-2 and MMP-9. [3] A composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, comprising carbazochrome as an active ingredient. [4] A composition for inhibiting gingipain activity, containing carbazochrome as an active ingredient. [5] A composition for inhibiting the activity of the basic amino acid gingipain, which contains carbazochrome as an active ingredient. [6] A composition for inhibiting activity described in any one of [1] to [5], which is an oral composition. [7] A composition for suppressing activity described in any one of [1] to [6], further comprising at least one compound selected from the group consisting of zinc chloride and erythorbic acid. [8] A method for producing a composition for inhibiting the activity of collagen-degrading proteases in oral tissue, comprising the step of incorporating carbazochrome into an oral composition. [9] A method for producing a composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, the method comprising the step of incorporating carbazochrome into an oral composition.

[0010] Furthermore, according to the present invention, for example, it is possible to provide an inhibitor of the activity of collagen-degrading proteases in oral tissues, which comprises carbazochrome as an active ingredient. The present invention also provides, for example, use of the activity inhibitor of the present invention for the manufacture of a composition for preventing inflammation of oral tissue. Effect of the Invention

[0011] According to the present invention, a new technique for inhibiting the activity of collagen-degrading proteases in oral tissues can be provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Hereinafter, an embodiment of the present invention will be described. In this embodiment, the composition may contain each component alone or in combination of two or more kinds.

[0013] (Composition for suppressing activity) In this embodiment, the composition for inhibiting activity is a composition for inhibiting the activity of collagen-degrading proteases in oral tissues, and contains carbazochrome as an active ingredient. Furthermore, the activity-suppressing composition is specifically an activity suppressor of collagen-degrading proteases in oral tissues, and may be an activity inhibitor of collagen-degrading proteases in oral tissues.

[0014] In this embodiment, the activity-inhibiting composition contains carbazochrome as an active ingredient, so that the activity of collagen-degrading proteases in oral tissues can be effectively inhibited. Furthermore, according to this embodiment, for example, a composition for inhibiting activity can be obtained that has an excellent effect of inhibiting the activity of collagen-degrading proteases in oral tissues and has a high degree of freedom in the range of application. In other words, by using the activity-inhibiting composition of this embodiment, for example, the decomposition of collagen in oral tissue can be suitably inhibited, and therefore, it is also possible to effectively inhibit the occurrence of inflammation in oral tissue, such as gingivitis and periodontitis, itself. Furthermore, according to this embodiment, for example, an activity suppressing composition with reduced odor can be obtained, which also makes it possible to improve the degree of freedom in the range of application of the activity suppressing composition.

[0015] The composition for suppressing activity will now be described in more detail. First, oral tissue collagen and oral tissue collagen-degrading proteases will be described. Oral tissue collagen is specifically collagen contained in oral tissue, more specifically collagen contained in oral soft tissue such as gingiva, periodontal ligament, mucosa, etc. Collagen is one of the components of oral tissue, and for example, most of the gums are composed of collagen. Furthermore, the oral tissue collagen is, for example, one or more types selected from the group consisting of type I collagen, type III collagen, and type IV collagen.

[0016] The oral tissue collagen-degrading protease is specifically a protease involved in the degradation of oral tissue collagen, and more specifically a protease that degrades oral tissue collagen. An oral tissue collagen-degrading protease is, for example, a protease whose substrate is oral tissue collagen, and more specifically, a protease whose substrate is one or more types of collagen selected from the group consisting of type I collagen, type III collagen, and type IV collagen. Furthermore, the oral tissue collagen-degrading protease may be a protease causing periodontal disease, such as a cysteine ​​protease produced by periodontal disease-causing bacteria.

[0017] The oral tissue collagen-degrading protease may, for example, be at least one selected from the group consisting of cysteine ​​proteases produced by periodontal disease-causing bacteria and matrix metalloproteinases (MMPs). Specific examples of each enzyme are given below.

[0018] A specific example of the cysteine ​​protease produced by periodontal disease causative bacteria is gingipain. From the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, the gingipain is preferably a basic amino acid-gingipain, more preferably at least one basic amino acid-gingipain selected from the group consisting of Arg-gingipain (Rgp) and Lys-gingipain (Kgp), and even more preferably Kgp.

[0019] In this embodiment, from the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, the activity-inhibiting composition is preferably a composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, which contains carbazochrome as an active ingredient, more preferably a composition for inhibiting gingipain activity, which contains carbazochrome as an active ingredient, and even more preferably a composition for inhibiting basic amino acid-gingipain activity, which contains carbazochrome as an active ingredient.

[0020] Specific examples of periodontal pathogens include one or more species selected from the group consisting of Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), Treponema denticola (Td), Actinobacicclus actino-mycetemcomitans (Aa) and Prevotella intermedia (Pi). From the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, the periodontal pathogen is preferably Pg. The fimA genotype of Pg includes types I to V and Ib. From the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, Pg is preferably fimAI type Pg, more preferably wild type (fimAI type) Pg.

[0021] Specific examples of MMPs include MMPs that use oral tissue collagen as a substrate. From the viewpoint of improving the activity-suppressing effect of the activity-suppressing composition, the MMP preferably uses at least one type selected from the group consisting of type I collagen and type IV collagen as a substrate. From a similar viewpoint, the MMPs is preferably at least one selected from the group consisting of MMP-1, MMP-2 and MMP-9.

[0022] From the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, the oral tissue collagen-degrading protease is preferably at least one selected from the group consisting of cysteine ​​proteases produced by periodontal disease-causing bacteria and MMP-1, MMP-2 and MMP-9.

[0023] The inhibition of the activity of oral tissue collagen-degrading proteases specifically means reducing or eliminating the activity of oral tissue collagen-degrading proteases, and more specifically means reducing or eliminating the proteolytic activity of oral tissue collagen-degrading proteases. The proteolytic activity is specifically the activity of degrading oral tissue collagen.

[0024] In the present embodiment, the activity suppression composition is specifically a composition used for the above-mentioned activity suppression, and contains carbazochrome as an active ingredient. As the carbazochrome, for example, a commercially available product can be used.

[0025] From the viewpoint of improving the activity-inhibiting effect of the activity-inhibiting composition, the concentration of carbazochrome in the activity-inhibiting composition is preferably 10 μM or more, more preferably 50 μM or more, even more preferably 0.1 mM or more, and even more preferably 0.5 mM or more. In addition, the concentration of carbazochrome in the activity suppressing composition is preferably 100 mM or less, and more preferably 90 mM or less.

[0026] From the viewpoint of improving the activity suppressing effect of the activity suppressing composition, the content of carbazochrome in the activity suppressing composition may be, for example, 0.0005 mass% or more, preferably 0.003 mass% or more, and more preferably 0.01 mass% or more, and may be, for example, 0.03 mass% or more, based on the entire activity suppressing composition. From the viewpoint of improving solubility, the content of carbazochrome in the activity suppressing composition is preferably 2 mass % or less, and more preferably 0.2 mass % or less, based on the entire activity suppressing composition.

[0027] The activity suppressing composition may further contain components other than the carbazochrome component. Such components may be selected depending on, for example, the intended use and formulation. Furthermore, the activity suppressing composition may be used, for example, as a pharmaceutical or quasi-drug.

[0028] Examples of the component other than the carbazochrome component include at least one compound selected from the group consisting of zinc chloride, erythorbic acid and its salts. Examples of the salts of erythorbic acid include alkali metal salts such as sodium salts and potassium salts. In addition, from the viewpoint of obtaining a preferable synergistic effect when the activity-suppressing composition is contained in the activity-suppressing composition together with carbazochrome, the activity-suppressing composition further contains at least one compound selected from the group consisting of zinc chloride and erythorbic acid. In this case, the activity-suppressing composition is preferably an oral composition described below.

[0029] The content of zinc chloride in the activity suppressing composition is preferably 0.00005 mass% or more, more preferably 0.0005 mass% or more, and even more preferably 0.005 mass% or more, based on the total mass of the activity suppressing composition, from the viewpoint of obtaining a favorable synergistic effect when zinc chloride is contained in the activity suppressing composition together with carbazochrome. The content of zinc chloride in the activity suppressing composition is preferably 1 mass % or less, more preferably 0.5 mass % or less, and even more preferably 0.1 mass % or less, based on the entire activity suppressing composition, thereby making it possible to reduce the metallic taste of zinc.

[0030] The content of erythorbic acid in the activity suppressing composition is preferably 0.005% by mass or more, more preferably 0.01% by mass or more, and even more preferably 0.05% by mass or more, based on the entire activity suppressing composition, from the viewpoint of obtaining a favorable synergistic effect when it is included in the activity suppressing composition together with carbazochrome. From the same viewpoint, the content of erythorbic acid in the activity suppressing composition is preferably 1 mass % or less, more preferably 0.5 mass % or less, and even more preferably 0.1 mass % or less, based on the entire activity suppressing composition.

[0031] From the viewpoint of obtaining a favorable synergistic effect when zinc chloride is contained in the activity suppressing composition together with carbazochrome, the mass ratio of the zinc chloride content to the carbazochrome content in the activity suppressing composition (zinc chloride / carbazochrome) is preferably 0.02 to 0.2, more preferably 0.055 to 0.065, when the composition is an activity suppressing composition for Rgp, and is preferably 0.05 to 0.06, when the composition is an activity suppressing composition for Kgp. In addition, the mass ratio of the erythorbic acid content to the carbazochrome content in the activity-inhibiting composition (erythorbic acid / carbazochrome) is, from the viewpoint of obtaining a favorable synergistic effect when it is contained in the activity-inhibiting composition together with carbazochrome, preferably 20 to 200, more preferably 60 to 65 when the composition is an activity-inhibiting composition for Rgp, and preferably 8 to 9 when the composition is an activity-inhibiting composition for Kgp.

[0032] (Oral composition) From the viewpoint of improving the activity-suppressing effect of the activity-suppressing composition, the activity-suppressing composition is preferably applied to the oral cavity. From the same viewpoint, the activity-suppressing composition is preferably a composition for oral cavity use. Specific examples of oral compositions include one selected from the group consisting of dentifrices such as toothpaste, liquid dentifrice, and tooth powder; oral coating agents such as oral gel preparations, oral ointments, oral pastes, and oral pastes; oral patches such as gum-adherent tape preparations; mouthwashes (mouthwashes); oral pills; oral tablets; oral powders; oral powders; oral liquids; oral suspensions; oral emulsions; oral granules; gums; lozenges; and buccal forms. Furthermore, the oral composition may be in the form of, for example, a liquid, a semi-solid, or a solid.

[0033] Regarding the amount of the oral composition to be applied to the oral cavity, the amount of carbazochrome to be applied per day is preferably 0.002 mg or more, more preferably 0.2 mg or more, from the viewpoint of improving the effect of inhibiting the activity of collagen-degrading proteases in oral tissues. From the viewpoint of safety, the daily dosage of carbazochrome is preferably 30 mg or less. The oral composition may be applied to the oral cavity, for example, 1 to 10 times per day, and preferably 1 to 5 times per day.

[0034] (Other ingredients) When the activity-suppressing composition is an oral composition, the oral composition may contain components other than the above-mentioned components within the scope of not impairing the effects of the present invention. Such ingredients include, for example, medicinal ingredients, abrasives, binders, thickeners, surfactants, flavorings, preservatives, fragrances, colorants, pH adjusters, solvents, solubilizers, bases, detergents, adsorbents, etc., and may be appropriately selected depending on the dosage form. Specific examples of additive ingredients are shown below, but the ingredients that can be added in the present invention are not limited to these.

[0035] Examples of the medicinal ingredient include one or more selected from the group consisting of bactericides, anti-inflammatory agents, blood circulation promoters, tartar deposition inhibitors, stain removers, dentin hypersensitivity inhibitors, vitamins, and plaque decomposing enzymes. There is no limitation on these medicinal ingredients as long as they can be used in medicines, oral compositions, etc.

[0036] Among the medicinal ingredients, examples of the bactericide include one or more selected from the group consisting of isopropylmethylphenol, cetylpyridinium chloride, cetylpyridinium chloride hydrate, benzalkonium chloride, benzethonium chloride, hinokitiol, chlorhexidine hydrochloride, alkyldiaminoethylglycine hydrochloride, sodium lauroyl sarcosine, and triclosan. The content of the bactericide in the oral cavity composition can be, for example, 0.01 to 1% by mass based on the total oral cavity composition.

[0037] Examples of anti-inflammatory agents include one or more selected from the group consisting of β-glycyrrhetinic acid, glycyrrhetinic acid, glycyrrhizinic acid, diammonium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, dipotassium glycyrrhizinate (dipotassium glycyrrhizinate), monoammonium glycyrrhizinate, tranexamic acid, ε-aminocaproic acid, sodium azulene sulfonate hydrate, allantoin, allantoin dihydroxyaluminum, epidihydrocholesterol, dihydrocholesterol, and lysozyme hydrochloride. The content of the anti-inflammatory agent in the oral cavity composition can be, for example, 0.01 to 1% by mass based on the entire oral cavity composition.

[0038] The blood circulation promoter may, for example, be at least one selected from the group consisting of sodium chloride and tocopherol acetate. The content of the blood circulation promoter in the oral composition can be, for example, 0.01 to 40% by mass based on the total oral composition.

[0039] Examples of tartar deposit inhibitors include one or more selected from the group consisting of zeolite, disodium hydrogen phosphate, disodium dihydrogen pyrophosphate, sodium pyrophosphate, anhydrous sodium pyrophosphate, tetrasodium pyrophosphate (anhydrous), disodium monohydrogen phosphate, sodium hydrogen phosphate hydrate, disodium hydrogen phosphate (crystalline), trisodium phosphate, and sodium polyphosphate.

[0040] Examples of stain removers include one or more selected from the group consisting of macrogol (Macrogol 200, Macrogol 300, Macrogol 400, Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, Macrogol 20000, etc.), sodium polyphosphate, and polyvinylpyrrolidone.

[0041] The dentin hypersensitivity reducing agent may, for example, be at least one selected from the group consisting of potassium nitrate and aluminum salts.

[0042] Examples of vitamin preparations include one or more selected from the group consisting of ascorbic acid, L-ascorbic acid, sodium ascorbate, L-sodium ascorbate, pyridoxine hydrochloride, DL-α-tocopherol acetate, tocopherol acetate, dl-α-tocopherol nicotinate, tocopherol nicotinate, and panthenol. The content of the vitamin preparation in the oral cavity composition can be, for example, 0.1 to 5% by mass based on the entire oral cavity composition.

[0043] An example of a plaque decomposing enzyme is dextranase.

[0044] Examples of the abrasive include one or more types selected from the group consisting of silica-based abrasives such as silicic acid anhydride, silica (crystalline silica or amorphous silica), silica gel, and aluminosilicate; zeolite, calcium hydrogen phosphate anhydrate, calcium hydrogen phosphate dihydrate, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, magnesium triphosphate, zirconium silicate, calcium triphosphate, hydroxyapatite, calcium quaternary phosphate, and synthetic resin-based abrasives. The content of the abrasive in the oral composition can be, for example, 1 to 40% by mass based on the entire oral composition.

[0045] Examples of the binder include one or more selected from the group consisting of organic binders such as pullulan, gelatin, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinylpyrrolidone, and carboxyvinyl polymers, thickening anhydrous silicic acid, and bentonite. The content of the binder in the oral cavity composition can be, for example, 0.5 to 5% by mass based on the entire oral cavity composition.

[0046] The thickening agent may be any one that is commercially available as a pharmaceutical, food, or cosmetic ingredient, and specifically includes one or more selected from the group consisting of polyhydric alcohols, sorbitol, glycerin, concentrated glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, propanediol (1,3-propanediol), polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, trehalose, sodium hyaluronate, and hydrolyzed collagen. Other examples of the binder include cetanol and stearyl alcohol. Of these, sorbitol may be added as, for example, sorbitol liquid (70%). The content of the thickener in the oral composition can be, for example, 1 to 30% by mass based on the entire oral composition.

[0047] Specific examples of the surfactant include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants, and preferably, one or more surfactants selected from the group consisting of anionic surfactants, nonionic surfactants, and amphoteric surfactants.

[0048] Examples of anionic surfactants include one or more selected from the group consisting of N-acylamino acid salts, α-olefin sulfonates, N-acylsulfonates, alkyl sulfates (sodium lauryl sulfate, sodium laureth sulfate, etc.), and sulfates of glycerin fatty acid esters. The content of the anionic surfactant in the oral cavity composition can be, for example, 0.01 to 3 mass % based on the total oral cavity composition. Examples of nonionic surfactants include one or more selected from the group consisting of polyoxyethylene alkyl ethers, polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene hydrogenated castor oils such as polyoxyethylene hydrogenated castor oil 60, polyethylene glycol fatty acid esters such as polyethylene glycol monooleate (10E.O.), polyoxyethylene ethers of glycerin esters, sucrose fatty acid esters, alkylolamides, glycerin fatty acid esters, and sorbitan fatty acid esters such as sorbitan monostearate. The content of the nonionic surfactant in the oral cavity composition can be, for example, 0.1 to 10% by mass based on the total oral cavity composition. Examples of amphoteric surfactants include one or more selected from the group consisting of alkyl betaine surfactants, amine oxide surfactants, and imidazolinium betaine surfactants, and specific examples thereof include 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine and coconut oil fatty acid amido alkyl betaine (e.g., coconut oil fatty acid amido propyl betaine). The content of the amphoteric surfactant in the oral cavity composition can be, for example, 0.1 to 3% by mass based on the total oral cavity composition.

[0049] Examples of flavoring agents include one or more selected from the group consisting of sodium L-glutamate, saccharin, sodium saccharin, disodium glycyrrhizinate, trisodium glycyrrhizinate, sucrose, glucose, fructose, lactose, honey, aspartame, stevia, sucralose, xylitol, inositol, D-sorbitol, sorbitol liquid, D-mannitol, arabitol, raffinose, lactulose, lactitol, erythritol, reduced palatinose, palatinose, palatinit, acesulfame K, maltose, maltosyl trehalose or maltitol, neohesperidin dihydrochalcone, perillartine, p-methoxycinnamic aldehyde, and thaumatin. The content of the flavoring agent in the oral cavity composition can be, for example, 0.1 to 40% by mass based on the entire oral cavity composition.

[0050] Examples of preservatives include one or more selected from the group consisting of paraoxybenzoic acid esters such as sodium benzoate, methylparaben, ethylparaben, butylparaben, isopropylparaben, propylparaben, isobutylparaben, and benzylparaben; alcohols such as phenoxyethanol and ethanol; sorbic acid, benzoic acid, dehydroacetic acid, propionic acid, and salts thereof; ethylenediaminetetraacetate; and alkyldiaminoethylglycine hydrochloride. The content of the preservative in the oral cavity composition can be, for example, 0.1 to 1% by mass based on the entire oral cavity composition.

[0051] The flavoring agent may, for example, be one or more selected from the group consisting of L-menthol, peppermint, spearmint, fruit flavorings, and peppermint oil. The content of the flavor in the oral cavity composition can be, for example, 0.1 to 5% by mass based on the total oral cavity composition.

[0052] Examples of colorants include one or more selected from the group consisting of natural colorants such as safflower red colorant, gardenia yellow colorant, gardenia blue colorant, perilla colorant, red koji colorant, red cabbage colorant, carrot colorant, hibiscus colorant, cacao colorant, spirulina blue colorant, and coumarind colorant; legal colorants such as Red No. 3, Red No. 104, Red No. 105, Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 3, and Blue No. 1; riboflavin, and titanium dioxide.

[0053] Examples of pH adjusters include one or more selected from the group consisting of acids and alkalis and buffers, such as acetic acid, hydrochloric acid, sulfuric acid, nitric acid, citric acid, phosphoric acid, malic acid, gluconic acid, maleic acid, succinic acid, glutamic acid, pyrophosphoric acid, tartaric acid, sodium hydroxide acetate, potassium hydroxide, sodium acetate, sodium carbonate, sodium citrate, sodium hydrogen citrate, phosphoric acid, sodium phosphate, sodium monohydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate. The content of the pH adjuster in the oral cavity composition can be, for example, 0.01 to 3% by mass based on the total oral cavity composition.

[0054] Examples of the solvent include water and lower alcohols such as ethanol and propanol. The content of the solvent in the oral cavity composition can be, for example, 10 to 90% by mass based on the entire oral cavity composition.

[0055] The solubilizer may be added, for example, to promote dissolution of the additives and medicinal ingredients in water. Examples of such solubilizers include polyhydric alcohols such as propylene glycol, dipropylene glycol, butylene glycol, and polyethylene glycol.

[0056] The base may, for example, be sodium bicarbonate. Examples of the base of the ointment include one or more selected from the group consisting of stearyl alcohol, stearic acid, cetanol, concentrated glycerin, and macrogol (Macrogol 400, Macrogol 4000, etc.). The content of the base in the oral cavity composition can be, for example, 1 to 99% by mass based on the entire oral cavity composition.

[0057] Detergents include, for example, sodium polyphosphate.

[0058] The adsorbent may, for example, be β-cyclodextrin.

[0059] Furthermore, in addition to the above-mentioned components, components generally suitable for use in oral compositions can also be appropriately blended within the scope of the present invention.

[0060] (Manufacturing method) In this embodiment, the method for producing a composition for inhibiting the activity of collagen-degrading proteases in oral tissues includes, for example, a step of blending carbazochrome into an oral composition. Such a production method is preferably a method for producing a composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria. The specific manufacturing procedure for the activity suppressing composition can be selected depending on, for example, the dosage form of the activity suppressing composition.

[0061] Although the embodiments of the present invention have been described above, these are merely examples of the present invention, and various configurations other than those described above can also be adopted. EXAMPLES

[0062] The present embodiment will be specifically described below with reference to examples, but the present embodiment is not limited to these examples.

[0063] In the examples below, the following ingredients were used: Carbazochrome: Sanwa Chemical Co., Ltd. Hinokitiol: Fujifilm Wako Pure Chemical Industries, Ltd. Dipotassium glycyrrhizinate: Manufactured by Maruzen Pharmaceuticals Tocopherol acetate: Eisai Co., Ltd. Concentrated glycerin: Concentrated glycerin for cosmetics, manufactured by Sakamoto Pharmaceutical Industry Co., Ltd. Citric acid: Kanto Chemical Co., Ltd. Sodium citrate: Kanto Chemical Co., Ltd. Phenoxyethanol: Yokkaichi Chemical Co., Ltd. Isopropyl methylphenol: Osaka Chemical Industry Co., Ltd. Polyoxyethylene hydrogenated castor oil 60: Nikko Chemicals Macrogol 400: NOF Corporation Macrogol 4000: NOF Corporation Cetylpyridinium chloride hydrate: MERCK Allantoin: Fujifilm Wako Pure Chemical Industries, Ltd. Sodium carboxymethylcellulose: CMC Daicel 1150, manufactured by Daicel Miraize Co., Ltd. Sorbitol solution: Kao Corporation Propylene glycol: ADEKA Sodium laureth sulfate: manufactured by Nacalai Tesque

[0064] (Test Example 1) Measurement of enzyme inhibitory activity In this example, the inhibitory activity against periodontal pathogenic bacteria secreted enzymes and MMPs was measured.

[0065] (Measurement of gingipain inhibitory activity) The inhibitory activity against gingipains (Rgp and Kgp), which are enzymes secreted by Poryphyromonas gingivalis, was measured by the following procedure. The results are shown in Table 1 (Tables 1-1 and 1-2).

[0066] (Preparation of enzyme solution) In the anaerobic chamber, 10 mL of 0.7% glucose-added GAM broth (Jpn J Periodontol 46:118-126, 2004) was dispensed into a disposable 15 mL centrifuge tube, 0.1 mL of a thawed frozen stock of a bacterial strain (Porphyromonas gingivalis, ATCC 33277 Wild type (fimA type I)) was inoculated, and the tubes were cultured anaerobically at 37°C for 24 hours. In addition, 25 mL of 0.7% glucose-added GAM broth was dispensed into a disposable 50 mL centrifuge tube, 0.25 mL of the bacterial suspension of the bacterial strain was inoculated, and the tubes were cultured anaerobically at 37°C for 24 hours. These cultures were removed from the anaerobic chamber and centrifuged at 1,100 rpm at 4°C for 5 minutes, and the supernatants were transferred to new disposable 50 mL centrifuge tubes. An equal amount of 80% ammonium sulfate to the culture supernatant was added under ice cooling, and after thorough stirring, the mixture was centrifuged at 10,000×g at 4°C for 30 minutes. After removing the supernatant, a sufficient amount of ice-cold buffer A (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM CaCl2) was added to the sediment to completely dissolve it. Then, 0.5 mL of the lysate of each strain was dialyzed overnight in buffer A supplemented with 0.02% Tween 20 using a Slide-A-Lyzer Dialysis Cassette kit (Thermo SCIENTIFIC, Thermo Fisher Scientific) with a Membrane Molecular-Weight Cutoff of 10,000 and a cassette size of 0.1-0.5 mL. The dialysis method was performed according to the kit's instructions. The solution recovered from the cassette was centrifuged at 7,000×g for 10 minutes at 4°C, and the supernatant after removing the sediment was used as concentrated Pg supernatant.

[0067] (Method for measuring enzyme inhibitory activity) The concentrated Pg supernatant diluted 1.10 times and the test substance were added at a volume ratio of 1:1, and preincubated (using a 96-well plate, 37°C, 10 minutes). Carbazochrome (Example 1) and hinokitiol (Control Example 1) were used as test substances. 2. An enzyme substrate (final concentration 10 μM) was added and incubated for 10 minutes. Z-His-Glu-Lys-MCA (Peptide Institute) was used as the substrate for Rgp, and Bz-Arg-MCA (Peptide Institute) was used as the substrate for Kgp. 3. Fluorescence intensity of the substance released from the substrate was measured using Enspire (PerkinElmer, Ex / Em 380 / 460 nm), and the value of the blank solution was subtracted from the fluorescence intensity, and the enzyme inhibitory activity was calculated according to the following formula. Enzyme inhibitory activity (%) = 100-(fluorescence intensity of measured sample / fluorescence intensity of control) x 100 The control group was treated with the pH 7.4 phosphate buffer used to dilute the test substance instead of the test substance. The experiment was performed with N=3, and the average enzyme inhibitory activity values ​​obtained are shown in Table 1 (Tables 1-1 and 1-2).

[0068] (Measurement of MMPs inhibitory activity) Carbazochrome was used as the test substance (Example 1), and its inhibitory activity against MMPs (MMP-1, MMP-2, and MMP-9) was measured according to the following procedure. The results are shown in Table 1 (Tables 1-3 to 1-5).

[0069] (Method for measuring enzyme inhibitory activity) To measure MMP-1 inhibitory activity, an MMP-1 Inhibitor Screening Kit (BioVision, #K794-100) was used, and the experiment was carried out as follows. 1. 50 μL of MMP-1 enzyme solution diluted with buffer was added to a 96-well plate, and then 25 μL of carbazochrome aqueous solution was added so that the reaction solution had a final concentration of 0.1 mM or 1 mM. The plate was then gently shaken and incubated at 37°C for 5 minutes. 2. 25 μL of reaction solution containing MMP-1 substrate was added, and fluorescence was measured after 10 minutes (Enspire, PerkinElmer, Ex / Em 480 / 530 nm). The fluorescence value obtained by subtracting the value of the blank solution was used to calculate the enzyme inhibitory activity (%) according to the following formula. Table 1 (Table 1-3) shows the average value of N=3. Enzyme inhibitory activity (%) = 100-(fluorescence intensity of measured sample / fluorescence intensity of control) x 100 The control group was treated with only a buffer instead of the test substance.

[0070] To measure the MMP-2 and MMP-9 inhibitory activity, the MMP-2 / 9 Assay kit (Sonsolyte #AS-72224) was used with some modifications from the standard protocol, and the tests were performed according to the following procedure. 1. The required amount of MMP-2 / 9 enzyme solution was prepared to be 200 ng / mL. 2.4-Aminophenylmercuric acetate was added to the solution prepared in 1. so as to reach a final concentration of 1 mM, and the mixture was incubated at 37° C. for 1 hour. 50 μL of the solution from 3.2 and aqueous solutions of carbazochrome adjusted to final concentrations of 25 and 250 μM were added to a 96-well plate and incubated at 37° C. for 10 minutes. 4. 100 μL of the MMP-2 / 9 substrate provided with the kit was added to each well and incubated at 37° C. for 10 minutes. 5. Fluorescence was measured (Enspire, PerkinElmer, Ex / Em 480 / 530 nm), and the fluorescence value obtained by subtracting the value of the blank solution was used to calculate the enzyme inhibitory activity (%) according to the following formula. Table 1 (Tables 1-4 and 1-5) shows the average value of N=3. Enzyme inhibitory activity (%) = 100-(fluorescence intensity of measured sample / fluorescence intensity of control) x 100 The control group was treated with only a buffer instead of the test substance.

[0071] [Table 1]

[0072] From Table 1, it was confirmed that carbazochrome exhibits high inhibitory activity against Rgp and Kgp as well as MMP-1, MMP-2 and MMP-9. It was also confirmed that the enzyme inhibitory activity of carbazochrome is as effective as that of the case where hinokitiol described in Patent Document 2 is used (Control Example 1).

[0073] (Test Example 2) Mouthwash Of the components listed in Table 2, the components in Addition Order A were mixed and dissolved at 60° C. The components in Addition Order B were added to this and mixed to obtain the mouthwash of each example. The appearance of the mouthwash obtained in each case was visually observed. In addition, the odor of the mouthwash obtained in each case was evaluated. The odor was evaluated with reference to the base group (Mock) that did not contain each test substance. The results are shown in Table 2. The formulations shown in Table 2 and Tables 3 and 4 below are as follows. MOCK: Base HO prescription: Hinokitiol CSS formulation: Carbazochrome

[0074] [Table 2]

[0075] (Test Example 3) Oral ointment Among the components listed in Table 3, the component in the addition order A was mixed and dissolved at 80° C. The component in the addition order B was added to this, mixed and dispersed, and cooled to 50° C. Then, the component in the addition order C was added, mixed and dispersed, and cooled to room temperature to obtain the oral ointment of each example. The appearance of the oral ointment obtained in each example was visually observed. In addition, the odor of the mouthwash obtained in each example was evaluated. The odor was evaluated with reference to the base group (Mock) that did not contain each test substance. The results are shown in Table 3.

[0076] [Table 3]

[0077] (Test Example 4) Dentifrice composition Of the components listed in Table 4, the component in Addition Order B was heated and dissolved at 60° C. This was added to the component in Addition Order A and mixed. While stirring the mixture, the component in Addition Order C was added to obtain the dentifrice composition of each example. The appearance of the dentifrice composition obtained in each example was visually observed. In addition, the odor of the mouthwash obtained in each example was evaluated. The odor was evaluated with reference to a base group (Mock) that did not contain any of the test substances. The results are shown in Table 4.

[0078] [Table 4]

[0079] As can be seen from Tables 2 to 4, in each Example, the odor of the oral composition was suitably suppressed.

[0080] (Test Example 5) Measurement of enzyme inhibitory activity In this example, the inhibitory activity of the compositions against gingipains (Rgp and Kgp) was evaluated in accordance with Test Example 1, except for the points described below. The formulation of the compositions in each example is shown below. Example 5: Carbazochrome (CSS) 0.0001, 0.001, 0.1, 1 and 10 mM (above, 5 concentrations), solvent PBS Example 6: Zinc chloride (ZC) 0.0001, 0.01, 0.1, 1 and 10 mM (above, 5 concentrations), solvent PBS Example 7: Erythorbic acid (Es) 0.0001, 0.01, 0.1, 1 and 10 mM (above, 5 concentrations), solvent PBS From the activity inhibition rates obtained in Examples 5 to 7 above, the 50% activity inhibition concentration (IC 50 The results of the calculations are shown in Table 5 below.

[0081] [Table 5]

[0082] In addition, carbazochrome, zinc chloride, or erythorbic acid were added to the IC 50The components were combined in 1:3, 1:1, and 3:1 ratios based on the concentrations normalized by the above method, and the 50% activity inhibitory concentration calculated additively was divided by a common ratio of 2 into three levels to prepare four concentrations each. Using these combination components, the following Examples 8 and 9 were evaluated again in accordance with Test Example 1. Example 8: Carbazochrome and zinc chloride (ZC), four concentrations (solvent PBS) Example 9: Carbazochrome and erythorbic acid (Es), 4 concentrations (solvent PBS)

[0083] (Evaluation of synergistic effects) The combined effect of the ingredients was evaluated using an isobologram, with the 50% growth inhibition effect as an index. When carbazochrome is combined with another ingredient, the Combination Index (CI) value shown in the formula below is 1 if the gingipain inhibitory activity shows an additive effect, CI<1 if the inhibitor shows a synergistic effect, and CI>1 if the inhibitor shows an antagonistic effect. X in the formula below is ZC, Es, or CSS. CI=(D X1 / D X1_50 )+(D X2 / D X2_50 ) However, D Xi is the dose of the combination that shows 50% inhibitory effect when used in combination, D Xi_50 is the dose at which 50% of the activity is inhibited by itself.

[0084] The evaluation results of the synergistic effect are shown in Table 6. The results shown in Table 6 are the evaluation results calculated by calculating the concentration showing 50% inhibitory activity rate against Kgp and Rgp when the components are combined as calculated from Examples 8 and 9, relative to the concentration showing 50% inhibitory rate when each component is alone, and the CI value at each ratio is shown. As shown in Table 6, the composition containing carbazochrome in combination with zinc chloride or erythorbic acid exhibits synergistic effects at each ratio for Rgp, and can provide a more excellent inhibitory effect. Also, for Kgp, the composition containing carbazochrome in combination with zinc chloride or erythorbic acid in a 1:1 ratio exhibits a more excellent inhibitory effect due to the synergistic effects of these two.

[0085] [Table 6]

[0086] (Formulation example) Formulation examples of an ointment (Formulation Examples 1-1 and 1-2), a dentifrice (Formulation Examples 2-1 and 2-2), and a liquid for external use or a mouthwash (Formulation Examples 3-1 and 3-2) are shown in Tables 7 to 9. The amounts of ingredients in Tables 7 to 9 are in mass %.

[0087] [Table 7]

[0088] [Table 8]

[0089] [Table 9]

Claims

1. A composition for inhibiting the activity of collagen-degrading proteases in oral tissues, comprising carbazochrome as an active ingredient.

2. The activity-suppressing composition according to claim 1, wherein the oral tissue collagen-degrading protease is at least one selected from the group consisting of cysteine ​​proteases produced by periodontal disease-causing bacteria and matrix metalloproteinase (MMP)-1, MMP-2 and MMP-9.

3. A composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, comprising carbazochrome as an active ingredient.

4. A composition for inhibiting gingipain activity, comprising carbazochrome as an active ingredient.

5. A composition for inhibiting the activity of basic amino acid-gingipain, comprising carbazochrome as an active ingredient.

6. The activity-inhibiting composition according to claim 1 , which is an oral composition.

7. The activity suppressing composition according to claim 6, further comprising at least one compound selected from the group consisting of zinc chloride and erythorbic acid.

8. A method for producing a composition for inhibiting the activity of collagen-degrading proteases in oral tissue, comprising the step of incorporating carbazochrome into an oral composition.

9. A method for producing a composition for inhibiting the activity of cysteine ​​protease produced by periodontal disease-causing bacteria, comprising the step of incorporating carbazochrome into an oral composition.

Citation Information

Patent Citations

  • JP1984、26

  • Agent for periodontal tissue regeneration, method for periodontal tissue regeneration, agent for periodontal tissue proliferation and activation, and antiaging agent for periodontium

    JP2016153396A

  • Agent for inhibiting activity of periodontal pathogen-producing cysteine protease

    JP2020109071A